BU08028
BU08028 is a dual-functional agonist that targets both the μ-opioid peptide receptor (MOP) and the neuropeptide FQ receptor (NOP) . BU08028 activates the inhibitory G protein (Giα), thereby inhibiting the activity of adenylate cyclase (AC), resulting in a decrease in intracellular second messenger cyclic adenosine monophosphate (cAMP) levels, and suppressing the generation and transmission of pain signals. BU08028 can take effect within 30 minutes in mouse models of neuropathic pain and inflammatory pain, and its analgesic effect can last for up to 24 hours. BU08028 has excellent safety, no addiction, respiratory depression, or side effects. BU08028 can be used for pain research[1].
Product Specifications
CAS Number
[1333904-22-5]
UNSPSC
12352005
Target
Opioid Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Neurological Disease
Smiles
CO[C@@]12[C@@]3([H])[C@]45[C@@](C[C@]1([H])[C@](C)(O)C(C)(C)CC)(CC2)[C@@H](CC6=C5C(O3)=C(C=C6)O)N(CC4)CC7CC7
Molecular Formula
C30H43NO4
Molecular Weight
481.67
References & Citations
[1]Wang Y, et al. Research progress on the potential novel analgesic BU08028. Eur J Pharmacol. 2022 Jan 5;914:174678.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NOP Receptor/ORL1; μ Opioid Receptor/MOR
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
